Kathlyn Lim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1396489/publications.pdf

Version: 2024-02-01

		1163117	1474206	
9	207	8	9	
papers	citations	h-index	g-index	
9	9	9	268	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	Citations
1	Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients WithÂTreatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. Kidney International Reports, 2022, 7, 720-731.	0.8	23
2	Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. American Journal of Transplantation, 2022, 22, 1133-1144.	4.7	18
3	Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 109-116.	4.5	42
4	Obinutuzumab is Effective forÂthe Treatment of Refractory Membranous Nephropathy. Kidney International Reports, 2020, 5, 1515-1518.	0.8	37
5	The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 42-56.	4.7	27
6	Donor-derived Cell-free DNA Combined With Histology Improves Prediction of Estimated Glomerular Filtration Rate Over Time in Kidney Transplant Recipients Compared With Histology Alone. Transplantation Direct, 2020, 6, e580.	1.6	12
7	Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation. Transplantation, 2019, 103, 2666-2674.	1.0	19
8	Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection. Transplantation, 2019, 103, 262-272.	1.0	28
9	Cefotetan-Induced Hemolytic Anemia: Case Series and Review. Journal of Pharmacy Practice, 2019, 32, 679-682.	1.0	1